Mass Spectrometry Imaging to detect glioblastoma disease signature in a patient -derived xenograft murine model.

Prem Shankar

Mass Spectrometry Imaging to detect glioblastoma disease signature in a patient -derived xenograft murine model.

Research output: Contribution to conference › Poster

Abstract

Glioblastoma (GBM) is a highly aggressive form of brain cancer with a 5-year survival rate below 10%. Elucidating early disease signatures of GBM is important for identifying potential target pathways for therapeutic intervention. Here, we apply an untargeted Mass Spectrometry Imaging (MSI) approach to visualize metabolic and lipidomic perturbations occurring within the heterogeneous tumors.

Original language	English (US)
State	Published - Sep 22 2023
Event	UTMB GSBS Research Expo23 - University of Texas Medical Branch, Galveston, United States Duration: Sep 22 2023 → Sep 22 2023

Other

Other	UTMB GSBS Research Expo23
Country/Territory	United States
City	Galveston
Period	9/22/23 → 9/22/23

Cite this

@conference{f7eb4757c69f411cbd773edbef5ea332,

title = "Mass Spectrometry Imaging to detect glioblastoma disease signature in a patient -derived xenograft murine model.",

abstract = "Glioblastoma (GBM) is a highly aggressive form of brain cancer with a 5-year survival rate below 10%. Elucidating early disease signatures of GBM is important for identifying potential target pathways for therapeutic intervention. Here, we apply an untargeted Mass Spectrometry Imaging (MSI) approach to visualize metabolic and lipidomic perturbations occurring within the heterogeneous tumors. ",

author = "Prem Shankar",

year = "2023",

month = sep,

day = "22",

language = "English (US)",

note = "UTMB GSBS Research Expo23 ; Conference date: 22-09-2023 Through 22-09-2023",

}

TY - CONF

T1 - Mass Spectrometry Imaging to detect glioblastoma disease signature in a patient -derived xenograft murine model.

AU - Shankar, Prem

PY - 2023/9/22

Y1 - 2023/9/22

N2 - Glioblastoma (GBM) is a highly aggressive form of brain cancer with a 5-year survival rate below 10%. Elucidating early disease signatures of GBM is important for identifying potential target pathways for therapeutic intervention. Here, we apply an untargeted Mass Spectrometry Imaging (MSI) approach to visualize metabolic and lipidomic perturbations occurring within the heterogeneous tumors.

AB - Glioblastoma (GBM) is a highly aggressive form of brain cancer with a 5-year survival rate below 10%. Elucidating early disease signatures of GBM is important for identifying potential target pathways for therapeutic intervention. Here, we apply an untargeted Mass Spectrometry Imaging (MSI) approach to visualize metabolic and lipidomic perturbations occurring within the heterogeneous tumors.

M3 - Poster

T2 - UTMB GSBS Research Expo23

Y2 - 22 September 2023 through 22 September 2023

ER -

Mass Spectrometry Imaging to detect glioblastoma disease signature in a patient -derived xenograft murine model.

Abstract

Other

Fingerprint

Cite this